Three Autoimmune Therapeutics from Samsung Bioepis Surpass $400 Million in European Sales in H1

Benepharli Europe Sales Reach $250 Million... Widening Gap with Original Pharmaceuticals

Biosimilars for autoimmune disease treatment developed by Samsung Bioepis: Benepali, Imraldi, Flixabi (Photo by Samsung Bioepis)

[Asia Economy Reporter Kim Ji-hee] Three autoimmune disease treatments developed by Samsung Bioepis?Benepali, Imraldi, and Flixabi?recorded sales exceeding $400 million in Europe in the first half of this year.

According to Samsung Bioepis on the 23rd, European partner Biogen announced in its earnings report yesterday that the sales of three biosimilars for autoimmune diseases such as rheumatoid arthritis in Europe reached $407.5 million (approximately 460 billion KRW) in the first half of this year. This represents a 4.4% increase compared to the same period last year ($390.4 million).

Thanks to increased sales volume, Samsung Bioepis surpassed $400 million in sales again in the first half of this year, following the second half of last year ($405.3 million). These three treatments have been cumulatively prescribed to 240,000 patients in Europe.

In particular, Benepali (active ingredient etanercept) achieved sales of $243.2 million (approximately 275 billion KRW) in the first half. It holds the number one market share for this active ingredient in Europe, continuously widening the sales gap with the original drug 'Enbrel.' During the same period, Imraldi, a biosimilar of Humira, recorded sales of $113.5 million (approximately 128 billion KRW), and Flixabi, a biosimilar of Remicade, posted sales of $50.8 million (approximately 57 billion KRW).

A Samsung Bioepis official stated, "Despite fierce competition, we are strengthening our leadership in the European autoimmune disease biosimilar market through increased sales volume," adding, "We will expand our product portfolio into various fields such as ophthalmic disease treatments in the future."

This content was produced with the assistance of AI translation services.